New drug imetelstat targets rare blood cancer in phase 2 trial
NCT ID NCT07549451
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 2 trial tests the drug imetelstat in 30 adults with myelodysplastic/myeloproliferative neoplasms (MDS/MPN), a rare blood cancer. The goal is to see if imetelstat can help control the disease and to check for side effects. Participants receive the drug by IV, and the study is not yet recruiting.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- imetelstat
- What this could lead to
- If it works, this could point toward a new treatment option to control MDS/MPN, a rare blood cancer.
- What could go wrong
- This is an early Phase 2 trial with only 30 participants, so results may not apply widely. The drug may cause side effects or fail to control the disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC MYELOMONOCYTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a pill keep blood cancer at bay after a stem cell transplant?
- Can a Two-Drug combo tame a rare blood cancer?
- Can a new immunotherapy combo tame aggressive appendiceal cancer?
- Can a new drug shrink Hard-to-Treat adrenal tumors?
- Can a gentler chemo-radiation combo make stem cell transplants safer for blood cancers?
- Can a Drug-Radiation combo outsmart Treatment-Resistant colorectal cancer?